ArticleJournal of the National Cancer Center2026

Orelabrutinib, fludarabine, cyclophosphamide, and obinutuzumab (OFCG) for first-line treatment of chronic lymphocytic leukemia: a multicenter phase II trial (cwCLL-001 trial).

Yi Miao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.